Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.021 | 0.7 |
mRNA | GDC-0449 | FIMM | pan-cancer | AAC | 0.08 | 0.7 |
mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.02 | 0.7 |
mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.02 | 0.7 |
mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |